Pulmonary hypertension in systemic sclerosis

Rheumatic Disease Clinics of North America

Volumn 29, Issue 2, 2003, Pages 335-349

  Denton, Christopher P ^a   Black, Carol M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; UNIPROST; WARFARIN;

ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG COST; DRUG EFFICACY; EARLY DIAGNOSIS; EXERCISE; GENE MUTATION; HEALTH CARE COST; HEART CATHETERIZATION; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; OXYGEN THERAPY; PATHOGENESIS; PATIENT MONITORING; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROVOCATION TEST; PULMONARY HYPERTENSION; RENOVASCULAR HYPERTENSION; REVIEW; SPIROMETRY; SURVIVAL; SYSTEMIC SCLEROSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION;

EID: 0038799768     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00024-3     Document Type: Review

References (38)

1. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 2001;13(6):495-9.
2. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978;64(6):998-1004.
3. Sackner MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol 1996;17:542-59.
4. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
5. Thomson JR, Machado RD, Pauciulo MW, et al. 2000. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-5.
6. Rudarakanchana N, Flanagan JA, Chen H, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11(13):1517-25.
7. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345(5):325-34.
8. Trembath RC. Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity. J Heart Lung Transplant 2001;20(2):175.
9. Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002;29(11):2379-81.
10. Crilly A, Hamilton J, Clark CJ, et al. Analysis of transforming growth factor betal gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 2002;61(8):678-81.
11. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001;44(4):893-901.
12. Susol E, Rands AL, Herrick A, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology 2000;39:1332-6.
13. Watson M, Hally RJ, McCue PA, et al. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis. Arthritis Rheum 1996;39(2):341-6.
14. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford) 2000;39(11):1269-71.
15. Stratton RJ, Pompon L, Coghlan JG, et al. Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 2000;59(2):132-4.
16. Stratton RJ, Coghlan JG, Pearson JD, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998;91(8):561-6.
17. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68(1):92-102.
18. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001;19;88:E2-11.
19. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-86.
20. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21(10):1838-44.
21. Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98(14):1400-6.
22. Shi-Wen X, Denton CP, Dashwood MR, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116(3):417-25.
23. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108(2):241-50.
24. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36(2):239-43.
25. Chemla D, Castelain V, Herve P, et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20(5):1314-31.
26. British Cardiac Society Guidelines. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(Suppl 1):11-13.
27. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35(10):989-93.
28. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001;40(4):453-9.
29. Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001;120(5):1547-55.
30. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302.
31. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425-34.
32. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4.
33. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9.
34. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23.
35. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903.
36. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360(9337):895-900.
37. Allcock RJ, O'Sullivan JJ, Corris PA. Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001;44(7):1660-2.
38. Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000;5(3):38-43.